Discovery of a small peptide that activates both APCCdc20 and APCCdh1 in yeast, driving increased lifespan

This study identifies a small peptide, C43-4, which activates the Anaphase Promoting Complex (specifically APCCdh1 and APCCdc20) in yeast to reverse age-related substrate accumulation and extend both replicative and chronological lifespans, demonstrating conserved anti-aging effects in *C. elegans*.

The Gist

The Big Idea: Finding a "Reset Button" for Aging Cells

Imagine your body is a giant, bustling factory. Inside this factory, there are millions of workers (cells) doing their jobs. To keep the factory running smoothly, there is a strict Quality Control Manager called the APC (Anaphase Promoting Complex).

The APC's job is to spot broken or outdated tools (proteins) and throw them in the trash (degrade them) so new, fresh tools can be used. This keeps the factory clean and efficient.

The Problem: As the factory gets older (aging), the Quality Control Manager starts to get tired and lazy. They stop throwing away the broken tools. These old, broken tools pile up, causing chaos, errors, and eventually, the factory starts to break down. This is what we call aging and disease.

The Goal: The scientists in this paper wanted to find a way to wake up this tired Quality Control Manager, make them work harder, and see if that could make the factory (the cell) last longer and stay healthier.

---

The Detective Work: Searching for a Magic Peptide

The researchers knew that in young, healthy cells, the APC works great. But in old cells, it fails. They hypothesized: "If we can force the APC to work again in old cells, maybe we can reverse aging."

They needed a key to unlock the APC. They didn't want to use a heavy wrench (like a big drug); they wanted a tiny, precise tool. So, they went on a treasure hunt using a method called a "2-hybrid screen."

Think of this like a speed dating event for molecules. They threw thousands of tiny, random protein snippets (called peptides) at the APC to see which ones would "click" and stick to it.

Out of thousands of candidates, they found a few that stuck. One of them, a tiny 20-amino-acid chain they named C43-4, was the superstar.

The Discovery: C43-4 is the "Wake-Up Call"

When they tested this tiny peptide (C43-4), they found something amazing:

1. It wakes up the Manager: C43-4 didn't just stick to the APC; it actually activated it. It was like pouring a cup of strong coffee into the tired Quality Control Manager. Suddenly, the manager started throwing away the broken tools again.
2. It works on two types of shifts: Cells have two main modes:
   • The "Work Shift" (Dividing): Cells that are busy multiplying.
   • The "Rest Shift" (Quiescent): Cells that have stopped dividing and are just trying to survive (like neurons in your brain or skin cells).
   • Most drugs only work on the "Work Shift." But C43-4 worked on both. It extended the life of cells that were dividing and cells that were resting. This is huge because most of our body's cells are in the "Rest Shift."

The Proof: Turning Back the Clock

The researchers did a few clever experiments to prove C43-4 was the real deal:

• The "Trash Pile" Test: They looked at old yeast cells (a simple model for human cells). Normally, old cells have a massive pile of broken tools (proteins like Clb1 and Mps1). When they added C43-4, the pile disappeared! The APC was cleaning up again.
• The "Late Night" Test: They added C43-4 to cells that were already old and dying. Even though the cells were near the end of their life, the peptide gave them a second wind, extending their lifespan significantly. It proved that aging damage isn't permanent; it can be reversed.
• The "Worm" Test: To see if this worked in more complex animals, they tested it on worms (C. elegans). Just like in yeast, the worms lived longer when they had C43-4. This suggests the "magic" works across different species, from yeast to humans.

Why This Matters for Humans

Why should you care about yeast and worms? Because the machinery inside our cells is very similar.

• Cancer: Cancer cells are like factories that refuse to throw away broken tools, allowing them to grow out of control. C43-4 forces the factory to clean up, which can stop cancer growth.
• Neurodegeneration: Diseases like Alzheimer's happen when old, sticky proteins build up in brain cells. Since C43-4 works on "resting" cells (like neurons), it could potentially help clean up the brain and prevent memory loss.
• Longevity: This is the first time scientists have found a direct way to activate the specific part of the APC (called APC-Cdh1) that is responsible for keeping non-dividing cells healthy.

The Bottom Line

The scientists discovered a tiny, simple peptide (C43-4) that acts like a reset button for the cell's cleaning crew.

• Before: The cleaning crew gets tired with age, trash piles up, and the cell dies.
• After C43-4: The cleaning crew is energized, the trash is cleared, and the cell lives longer and stays healthier.

This discovery opens the door to new therapies that could not only help treat cancer but also potentially slow down the aging process and protect our brains from age-related diseases. It's a small key that might unlock a much longer, healthier life.

Technical Summary

1. Problem Statement

Cellular aging is driven by the loss of genome stability and proteostasis. The Anaphase Promoting Complex (APC), a conserved E3 ubiquitin ligase, is critical for cell cycle progression (mitosis via APC$^{Cdc20}$) and the maintenance of G1/G0 quiescence (via APC$^{Cdh1}$).

• The Gap: While APC dysfunction is linked to cancer and aging, current therapeutic strategies (e.g., Spindle Assembly Checkpoint inhibitors like M2I-1) primarily target APC$^{Cdc20}$ to force cancer cells into mitotic catastrophe. These agents do not activate APC$^{Cdh1}$, which is essential for the health of non-dividing, differentiated cells (e.g., neurons) and tumor suppression.
• The Hypothesis: The authors hypothesized that APC function declines during chronological aging, leading to the accumulation of toxic substrates. They proposed that a small peptide capable of directly activating APC$^{Cdh1}$ could reverse this decline, extend lifespan, and improve cellular health in non-dividing cells.

2. Methodology

The study employed a multi-organism approach combining yeast genetics, proteomics, and C. elegans models:

• Peptide Discovery: Utilized a yeast two-hybrid (Y2H) screen with a random peptide library (fused to the Thioredoxin A backbone) against APC subunits Apc5 and Apc10. Apc10 was chosen as the bait due to its role as a co-receptor for substrate recruitment.
• Yeast Models:
  • Strains: Used Saccharomyces cerevisiae (W303 and BY4741 backgrounds) with specific APC mutations (apc5$^{CA}$, apc10$\Delta$, cdc20-1, cdh1$\Delta$).
  • Lifespan Assays:
    • Replicative Lifespan (RLS): Measures cell divisions (requires both APC$^{Cdc20}$ and APC$^{Cdh1}$).
    • Chronological Lifespan (CLS): Measures survival of non-dividing quiescent cells (requires APC$^{Cdh1}$).
  • Protein Analysis: Used TAP-tagged substrates (Clb1, Mps1, Sic1) to monitor APC activity via Western blotting during aging and cell cycle re-entry.
  • Peptide Delivery: Tested peptides expressed from plasmids (inducible by galactose) and synthesized chemically (C43-4 fused to FITC) to verify direct effects without the TrxA backbone.
• C. elegans Models: Generated transgenic worms expressing C43-4 fused to GFP under the eft-3 promoter. Lifespan assays were conducted in wild-type and mutant backgrounds (daf-16, aak-2, akt-1) to test evolutionary conservation and pathway dependency.

3. Key Contributions

1. Discovery of C43-4: Identification of a specific 20-amino acid peptide (C43-4) that binds to the APC subunit Apc10 and activates the complex.
2. First APC$^{Cdh1}$ Activator: C43-4 is the first described molecule capable of specifically activating APC$^{Cdh1}$, distinct from SAC inhibitors that only target APC$^{Cdc20}$.
3. Reversibility of Aging Defects: Demonstrated that APC dysfunction in aging cells is not permanent; it can be reversed by peptide activation, restoring substrate degradation.
4. Mechanistic Insight: Revealed that C43-4 contains an RxxL motif (a D-box), mimicking APC substrates, which likely facilitates its interaction with the Apc10/co-activator complex to trigger activation.
5. Evolutionary Conservation: Proved that the lifespan-extending mechanism of C43-4 is conserved from yeast to nematodes, dependent on the AMPK/FOXO stress response pathways.

4. Key Results

• APC Dysfunction in Aging: Chronologically aging yeast cells showed a progressive accumulation of APC substrates (Clb1 and Mps1) in the G1 phase, while SCF-targeted Sic1 remained stable. This confirmed that APC activity specifically declines with age.
• Limitations of Chemical Activators: The chemical APC activator M2I-1 increased Replicative Lifespan (RLS) but failed to extend Chronological Lifespan (CLS), confirming it only affects APC$^{Cdc20}$ and not the quiescence-maintaining APC$^{Cdh1}$.
• Peptide Screening:
  • Several peptides slowed cell growth (indicating APC activation), but only C43-4 significantly extended both RLS and CLS in wild-type yeast.
  • C43-4 restored the short lifespan of apc5$^{CA}$ mutants and extended the CLS of wild-type cells even when added late in the aging process.
• Mechanism of Action:
  • Dependency: C43-4 required a functional APC and both co-activators (CDC20 and CDH1) to extend lifespan. It failed to extend CLS in cdc20-1, cdh1$\Delta$, or ama1$\Delta$ mutants.
  • Direct Entry: Synthetic C43-4 (C43-4$^{FITC}$) entered the nucleus without a carrier peptide (TAT2), likely due to a cluster of arginines acting as a nuclear localization signal.
  • Substrate Clearance: In aging cells expressing C43-4, Clb1 levels remained low, indicating the peptide successfully maintained APC activity throughout the aging process.
• C. elegans Validation:
  • Expression of C43-4 significantly extended worm lifespan.
  • This extension was abolished in daf-16 (FOXO ortholog) and aak-2 (AMPK ortholog) mutants, placing C43-4 within the conserved insulin/IGF-1 and AMPK stress response pathways.
  • In akt-1 mutants (which naturally live long), C43-4 provided no further benefit, suggesting C43-4 acts by inhibiting the AKT nutrient-sensing kinase.

5. Significance

• Therapeutic Potential: The discovery of C43-4 provides a novel strategy for targeting APC$^{Cdh1}$, which is crucial for maintaining the health of post-mitotic cells (e.g., neurons) and suppressing tumorigenesis. Unlike SAC inhibitors, C43-4 may protect differentiated cells from age-related decline.
• Reversibility of Aging: The study challenges the notion that APC decline is an irreversible hallmark of aging, showing that specific peptide activation can restore proteostasis and extend lifespan.
• Drug Development: C43-4 serves as a "proof-of-concept" and a structural blueprint for developing small molecule or peptide therapeutics that mimic the D-box motif to activate APC$^{Cdh1}$, potentially treating age-related diseases and neurodegeneration.
• Cancer Relevance: Given the link between APC$^{Cdh1}$ loss and cancer, and the previous finding that C43-4 stalls tumor growth in mouse models, this peptide offers a dual benefit: extending healthspan and acting as an anti-cancer agent.